BRNS Barinthus Biotherapeutics Plc.

Price (delayed)

$1.52

Market cap

$59.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

-$57.83M

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed ...

Highlights
Barinthus Biotherapeutics's EPS has increased by 3.7% from the previous quarter
The net income has grown by 3.6% from the previous quarter
BRNS's revenue has dropped by 99% year-on-year and by 58% since the previous quarter
The gross profit has dropped by 99% year-on-year and by 58% since the previous quarter

Key stats

What are the main financial stats of BRNS
Market
Shares outstanding
39.03M
Market cap
$59.33M
Enterprise value
-$57.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.34
Price to sales (P/S)
176.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-173.16
Earnings
Revenue
$334,000
EBIT
-$73.27M
EBITDA
-$66.23M
Free cash flow
-$62.79M
Per share
EPS
-$1.84
Free cash flow per share
-$1.62
Book value per share
$4.41
Revenue per share
$0.01
TBVPS
$4.2
Balance sheet
Total assets
$199.48M
Total liabilities
$27.47M
Debt
$12.81M
Equity
$171.83M
Working capital
$130.3M
Liquidity
Debt to equity
0.07
Current ratio
11.15
Quick ratio
10.13
Net debt/EBITDA
1.77
Margins
EBITDA margin
-19,828.7%
Gross margin
100%
Net margin
-21,173.1%
Operating margin
-23,755.7%
Efficiency
Return on assets
-31.8%
Return on equity
-36.7%
Return on invested capital
-228.3%
Return on capital employed
-39.3%
Return on sales
-21,938.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BRNS stock price

How has the Barinthus Biotherapeutics stock price performed over time
Intraday
2.7%
1 week
6.29%
1 month
-19.58%
1 year
-32.44%
YTD
-58.81%
QTD
8.57%

Financial performance

How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$334,000
Gross profit
$334,000
Operating income
-$79.34M
Net income
-$70.72M
Gross margin
100%
Net margin
-21,173.1%
The net margin has shrunk by 132% QoQ
The operating margin has plunged by 127% from the previous quarter
BRNS's revenue has dropped by 99% year-on-year and by 58% since the previous quarter
The gross profit has dropped by 99% year-on-year and by 58% since the previous quarter

Growth

What is Barinthus Biotherapeutics's growth rate over time

Valuation

What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.34
P/S
176.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-173.16
Barinthus Biotherapeutics's EPS has increased by 3.7% from the previous quarter
The stock's price to book (P/B) is 43% less than its last 4 quarters average of 0.6
The equity has contracted by 8% from the previous quarter and by 8% YoY
BRNS's revenue has dropped by 99% year-on-year and by 58% since the previous quarter
The P/S is 49% above the last 4 quarters average of 118.8

Efficiency

How efficient is Barinthus Biotherapeutics business performance
Barinthus Biotherapeutics's ROS has plunged by 130% from the previous quarter
Barinthus Biotherapeutics's return on invested capital has increased by 2.2% QoQ

Dividends

What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BRNS.

Financial health

How did Barinthus Biotherapeutics financials performed over time
The current ratio fell by 10% QoQ and by 10% YoY
Barinthus Biotherapeutics's quick ratio has decreased by 10% from the previous quarter and by 10% YoY
The debt is 93% lower than the equity
The equity has contracted by 8% from the previous quarter and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.